Select Publications

Alberts DS et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol 2006;103(3):783-92. Abstract

Alberts DS et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950-5. Abstract

Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43. Abstract

Bristow RE et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72(3):278-87. Abstract

Byrne AT et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9(15):5721-8. Abstract

Fruehauf JP et al. In vitro drug response and biomarker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971). Proc ASCO 2002;Abstract 2177.

Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4. Abstract

Hoskins WJ et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992;47(2):159-66. Abstract

Hu L et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11(19 Pt 1):6966-71. Abstract

Hunter RW et al. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166(2):504-11. Abstract

Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour? J Clin Oncol 2007;25(33):5150-2. No abstract available

Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: A brief critique and a call for action. J Clin Oncol 2007;25(27):4168-70. No abstract available

Markman M et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(4):1001-7. Abstract

Numnum TM et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006;102(3):425-8. Abstract

Sood AK et al. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731-7. Abstract

Wright JD et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107(1):83-9. Abstract

Xu L et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000;16(3):445-54. Abstract

Home

EDITOR
Neil Love, MD

INTERVIEWS

Robert F Ozols, MD, PhD
- Select publications

Maurie Markman, MD
- Select publications

Thomas J Herzog, MD
- Select publications

Ovarian Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office